This is a working overview of WADA prohibited list, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-01-19 and is reviewed periodically as new material appears.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
The head of the Ukrainian Defense Industry claimed that Ukraine's production of suicide drones identical to Shahed 131s and Shahed 136s had caught up with Russia's production of Shahed drones. He also claimed that Ukrainian manufacturing reached parity with Russia's production of other strike drones, and that Ukrainian forces have already used domestically produced drones similar to Russia's Lancet drones.
Phytochelatins are oligomers of glutathione, produced by the enzyme phytochelatin synthase. They are found in plants, fungi, nematodes and all groups of algae including cyanobacteria. Phytochelatins act as chelators, and are important for heavy metal detoxification. They are abbreviated PC2 through PC11. A mutant Arabidopsis thaliana lacking phytochelatin synthase is very sensitive to cadmium, but it grows just as well as the wild-type plant at normal concentrations of zinc and copper, two essential metal ions, indicating that phytochelatin is only involved in resistance to metal poisoning. Because phytochelatin synthase uses glutathione with a blocked thiol group in the synthesis of phytochelatin, the presence of heavy metal ions that bind to glutathione causes the enzyme to work faster. Therefore, the amount of phytochelatin increases when the cell needs more phytochelatin to survive in an environment with high concentrations of metal ions. Phytochelatin binds to Pb ions leading to sequestration of Pb ions in plants and thus serves as an important component of the detoxification mechanism in plants. Phytochelatin seems to be transported into the vacuole of plants, so that the metal ions it carries are stored safely away from the proteins of the cytosol.
== Etymology == The term parenchyma is Neo-Latin from the Ancient Greek word παρέγχυμα parenchyma meaning 'visceral flesh', and from παρεγχεῖν parenkhein meaning 'to pour in' from παρα- para- 'beside' + ἐν en- 'in' + χεῖν khein 'to pour'. Originally, Erasistratus and other anatomists used it for certain human tissues. Later, it was also applied to plant tissues by Nehemiah Grew.
=== Pregnancy and lactation === Its use in pregnant and lactating women is advised against, although the available evidence suggests it is unlikely to cause negative effects on fetal development. The lack of evidence from human studies, however, means it is currently impossible to rule out any risk to the fetus and it is known to cross the placenta. Doxepin is secreted in breast milk and neonatal cases of respiratory depression in association with maternal doxepin use have been reported.
== Contraindications == Voriconazole is toxic to the fetus, and thus not used in pregnant women, or women who may become pregnant. People with hereditary intolerance for galactose, Lapp lactase deficiency, or glucose-galactose malabsorption should not take this drug. It should be used cautiously in people with arrhythmias or a long QTc interval. No dose adjustment is necessary for renal impairment or advanced age, but children seem to clear voriconazole faster than adults, and drug levels may need monitoring.
Sources: en.wikipedia.org
Agustín Edwards Mac Clure, a person with marked anti-Peruvian sentiments, who from the beginning of his administration came to intensify Chile's "strong hand" policy in Tacna and Arica, renewing the Peruvian protests. The anti-Peruvian riots and attacks, as well as their anti-Chilean counterparts, constantly harassed the diplomatic missions of the countries, which is why several cities in Chile began to rearticulate the patriotic leagues, nationalist organizations responsible for much of the xenophobic violence that was unleashed against Peruvians and Bolivians residing in the country in the country that had annexed the provinces where they lived. According to Arnold McKay, former US consul in Antofagasta, Chile activated three strategies to achieve that objective. He founded Ligas Patrioticas, clandestine organizations inspired by the Ku Klux Klan, which expelled prosperous and influential Peruvians and Bolivians. He maintained strict censorship of Peruvian newspapers. Since 1918, he prescribed the appearance of resident or passing foreigners to register their fingerprints and show their nationality cards to the police. This measure arose to exclude extremists from the country, but in fact it served to find out how many Peruvians and Bolivians were in the area. From 1918 to 1922, the Chilean State and population were exposed to a real and fictitious "danger from the North". The nationalist feeling of the leagues was mainly marked by a fundamental anti-Peruvianism.
The Theodor Bilharz Research Institute is located in Giza, Egypt. Theodor Bilharz was a German scientist who discovered, in autopsy material at Kasr El Aini Hospital, the causative agent of haematuria: Schistosoma worm, during his work in Egypt in 1851. The bilhariziasis disease was named after him.
For example, if the first residue is a phenylalanine then the enzyme chymotrypsin will cleave at site 1, and if the third residue of the tripeptide is a lysine then trypsin would cleave at the third cleavage site.
==== Australia ==== The non-medical use of oxycodone existed since the early 1970s, but by 2015, 91% of a national sample of injecting drug users in Australia had reported using oxycodone, and 27% had injected it in the last six months.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.